Creative solution for the WPI/MNTA issue (ignoring the unknown financial exposure/litigation exposure that WPI has with Amphastar) is for WPI to offer a buyout of MNTA for $22 a share. They would have access to MNTA's cash hoard, access to perhaps $30-40 million income stream annually from m-enox, the NVS-Copaxone milestone payments,and possible future m-copax revenues. It would take the legal exposure off the table relating to MNTA and have a viable biosimilar program with a partner in place.
Would cost them less than $800 million to enact, assuming no additional bidder.
$22 price is a 35--40% market premium.
Market Data 
Markets 
AI
